Haeggquist & Eck, LLP Is Investigating Claims Against Regeneron Pharmaceuticals, Inc.’s Directors & Officers for Breach of ...
October 08 2020 - 9:00AM
Business Wire
Haeggquist & Eck, LLP, a leading shareholder rights
litigation firm, is investigating whether certain directors and
officers of Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ:
REGN) breached their fiduciary duties to Regeneron and its
shareholders. If you are a Regeneron shareholder, you are
encouraged to contact Amber Eck at Haeggquist & Eck for
additional information.
Haeggquist & Eck is investigating whether members of
Regeneron’s Board of Directors or senior management failed to
manage Regeneron in an acceptable manner, in breach of their
fiduciary duties to Regeneron, and whether Regeneron has suffered
damages as a result.
In January 2017, Regeneron received a subpoena from the U.S.
Attorney’s Office for the District of Massachusetts regarding
violations of federal anti-kickbacks statutes concerning use of
patient-assistance funds to encourage doctors to prescribe certain
of Regeneron’s drugs over less-expensive competitors.
In September 2019, Regeneron received a civil investigative
demand from the U.S. Department of Justice pursuant to the federal
False Claims Act investigating separate violations of federal
anti-kickback statutes.
On June 24, 2020, federal prosecutors in Massachusetts filed
suit against Regeneron, claiming violations of federal
anti-kickback statutes.
What You Can Do
If you are a Regeneron shareholder, you may have legal claims
against its directors and officers. If you wish to discuss this
investigation, or have questions about this notice or your legal
rights, please contact attorney Amber Eck at 619-342-8000 or e-mail
her at ambere@haelaw.com. There is no cost or obligation to
you.
Haeggquist & Eck, LLP is a nationally recognized leader in
shareholder rights law. The firm represents individual investors in
shareholder derivative lawsuits, and members of the firm have
helped shareholders recover more than $1 billion of value for
themselves and the companies in which they have invested.
This release constitutes attorney advertising. Past results do
not guarantee a similar outcome.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201008005249/en/
Haeggquist & Eck, LLP 619-342-8000 Amber Eck,
ambere@haelaw.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
